Phase 3 trial shows lanadelumab to be effective in reducing hereditary angioedema attacks

A phase 3 clinical trial finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema -- a rare, potentially life-threatening disorder.

from Latest Science News -- ScienceDaily https://ift.tt/2E0NpZL

Comments

Popular posts from this blog

Jared Leto Was Responsible for the "We Live in a Society" Line in the 'Zack Snyder's Justice League' Trailer - /FILM

How to keep Amazon, Apple, and Google from listening to your Alexa, Siri, and Assistant recordings - TechHive

Exclusive: IAEA found uranium traces at Iran 'atomic warehouse' - diplomats - Reuters